Biosciences – Talk Bio

Ascletis’ Sagimet-Sourced Oral FASN Inhibitor Achieves All Endpoints in Pivotal Acne Study

3 days ago talkbio0Tagged Acne Vulgaris, Ascletis, Biosciences, Chinese study, clinical endpoints, Clinical Trials, Denifanstat, Inhibitor, Lesion, oral FASN, Phase 3, Sagimet

Ascletis; Sagimet Biosciences; denifanstat; oral FASN inhibitor; phase 3 clinical trial; acne vulgaris; clinical endpoints; lesion reduction; Chinese study

Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures

4 weeks ago talkbio0Tagged Biosciences, Biotech Layoffs, Collaboration termination, Facility (object), IgM antibodies, Immunoglobulin M, Immunology, Inflammation, Neoplasms, Reparative closure, sanofi

Sanofi, IGM Biosciences, collaboration termination, biotech layoffs, facility closures, IgM antibodies, immunology, inflammation, oncology

Daiichi turns to Nosis for AI-designed RNA delivery tech

3 months ago talkbio0Tagged Biosciences, Cells, Chronic disease, Daiichi, Nosis, Partnership, RNA, Sankyo

Nosis, Daiichi, RNA, Sankyo, Partnership, Biosciences, Cells, Chronic disease

Novo Nordisk Pursues $830 Million Fraud Claim Against KBP Biosciences Over Failed Hypertension Drug

4 months ago talkbio0Tagged Arbitrating, asset, Biosciences, Clinical Trials, Failure (biologic function), Fraud, Freezing, Hypertensive disease, kilobase pairs, Nordisk, Ocedurenone

Novo Nordisk, KBP Biosciences, ocedurenone, fraud, asset freeze, clinical trial failure, hypertension drug, arbitration

Retro Biosciences, Backed by Sam Altman, Seeks $1 Billion to Extend Human Lifespan by 10 Years

4 months ago talkbio0Tagged Altman, Artificial (qualifier value), Biosciences, Biotechnology, Dorsal, Funding, Health care facility, Homo sapiens, Intelligence, Lifespan Extension, Series

Retro Biosciences, Sam Altman, Human Lifespan Extension, Biotechnology, Series A Funding, Artificial Intelligence in Healthcare

Leo Pharma Acquires EU Rights to Loqtorzi, Boosting Marketing Efforts for PD-1 Inhibitor

5 months ago talkbio0Tagged Biosciences, EU, Inhibitor, Junshi, Loqtorzi, Nasopharyngeal carcinoma, PDCD1 gene, Pharma, rights

Loqtorzi, PD-1 Inhibitor, Nasopharyngeal Carcinoma, EU Rights, Leo Pharma, Junshi Biosciences, Marketing Efforts

IGM Biosciences Halts Autoimmune Projects Amid Layoffs Following Disappointing Trial Data

5 months ago talkbio0Tagged Autoimmune Diseases, Biosciences, bispecific antibody T cell, engagers, IGM-2644, Immunoglobulin M, imvotamab, Industry

IGM Biosciences, layoffs, autoimmune diseases, bispecific antibody T cell engagers, imvotamab, IGM-2644, biotech industry

Shoreline Biosciences Reduces Staff Amid Uncertainty in Partnership with Gilead’s Kite

5 months ago talkbio0Tagged Biosciences, Cell Therapy, Gilead Sciences, Kite Pharma, Shoreline, strategic partnership

Shoreline Biosciences, Gilead Sciences, Kite Pharma, layoffs, cell therapy, strategic partnership

FDA Approves Neurocrine’s Crenessity for Rare Congenital Adrenal Hyperplasia

6 months ago talkbio0Tagged Adrenal Glands, Approved, Biosciences, Congenital adrenal hyperplasia, Crenessity, Hereditary Diseases, Neurocrine, United States Food and Drug Administration

Neurocrine Biosciences, FDA approval, Crenessity, crinecerfont, congenital adrenal hyperplasia (CAH), rare genetic disease, adrenal gland condition.

Coherus BioSciences Completes Strategic Shift with $483M Sale of Last Biosimilar Asset

6 months ago talkbio0Tagged Biosciences, Biosimilars, Biotechnology, Coherus, Drug Industry, strategic pivot

Coherus BioSciences, biosimilars, strategic pivot, pharmaceutical industry, biotechnology